<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Approach to the adult with pancytopenia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Approach to the adult with pancytopenia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Approach to the adult with pancytopenia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy Berliner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter Newburger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 31, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1143902330">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancytopenia refers to decreases in all peripheral blood lineages and is considered to be present when all three cell lines are below the normal reference range.
        </p>
        <p>
         Pancytopenia can be associated with a multitude of disease states, some of which are life threatening. A thoughtful history and physical examination along with focused laboratory studies are required to establish a diagnosis and select proper management. In most cases of pancytopenia, referral to a hematologist will be important for purposes of diagnosis and/or management.
        </p>
        <p>
         The diagnostic approach to an adult patient with pancytopenia will be discussed here. The evaluation of isolated neutropenia, anemia, and thrombocytopenia are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">
          "Diagnostic approach to thrombocytopenia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H115856">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancytopenia refers to decreases in all peripheral blood lineages. Many disorders that cause pancytopenia can also cause bicytopenia (ie, decreases in only two cell lines); thus, in most cases the evaluation of bicytopenia is similar to that presented here.
        </p>
        <p>
         Individual laboratories typically establish their own reference ranges for hemoglobin/hematocrit, white blood cell count, and platelet count. These institutional cutoff values supersede published reference standards such as those published by the World Health Organization [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red blood cells – Hemoglobin &lt;12 g/dL for non-pregnant women and &lt;13 g/dL for men
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White blood cells – Because neutrophils constitute the majority of leukocytes in the peripheral blood and bone marrow, nearly all cases of low white blood cells (leukopenia) manifest as neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Absolute neutrophil count (ANC) &lt;1800/microL – Calculated as the total white blood cells/microL x (percent [polymorphonuclear cells + bands] ÷ 100) (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelets – Platelet count &lt;150,000/microL
        </p>
        <p>
        </p>
        <p>
         Threshold levels for normal values may differ depending on age, sex, and race [
         <a href="#rid1">
          1
         </a>
         ]. Thresholds may also differ depending on the clinical scenario; as an example, different criteria are used to diagnose certain bone marrow failure syndromes (eg, aplastic anemia, myelodysplastic syndromes). (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15775.html" rel="external">
          "Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3678681518">
         <span class="h1">
          MECHANISMS OF PANCYTOPENIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematopoiesis (blood cell production) in the healthy adult takes place in the bone marrow, from which mature blood cells migrate into the circulation, spleen, and other sites. The bone marrow is a dynamic organ and a hematopoietic reservoir that responds to ongoing needs for blood cell production. A balance between blood cell production, distribution in other organs, and ongoing cellular destruction (eg, white blood cells fighting infections, platelet consumption in blood clots, cellular senescence) determines the levels of circulating blood cells [
         <a href="#rid2">
          2-5
         </a>
         ].
        </p>
        <p>
         Broadly speaking, pancytopenia may be caused by one or more of the following mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow infiltration/replacement – Such disorders include hematologic malignancies (eg, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes), metastatic cancer, myelofibrosis, and infectious diseases (eg, miliary tuberculosis, fungal infections).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow aplasia – Nutritional disorders (eg, deficiencies of vitamin B12 or folate), aplastic anemia, infectious diseases (eg, HIV, viral hepatitis, parvovirus B19), immune destruction, and medications are among the causes of marrow aplasia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood cell destruction or sequestration – Excessive blood cell destruction occurs in disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and ineffective hematopoiesis (eg, myelodysplastic syndromes, megaloblastic disorders), while excessive sequestration may be due to hypersplenism (eg, from liver cirrhosis, storage diseases, lymphoma, or autoimmune disorders).
        </p>
        <p>
        </p>
        <p>
         Some diseases may cause pancytopenia by multiple mechanisms. As an example, a lymphoma may infiltrate the bone marrow, cause hypersplenism, induce immune destruction of blood cells, and require treatment with cytotoxic agents. Similarly, Crohn disease may impair absorption of iron, folate, and vitamin B12; induce an inflammatory state that exacerbates anemia; require partial bowel resection that affects absorption of nutrients and calories; and require treatment with myelosuppressive agents.
        </p>
        <p class="headingAnchor" id="H1287772966">
         <span class="h1">
          CAUSES OF PANCYTOPENIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of causes of pancytopenia are categorized in the table by the predominant mechanism(s) of cytopenia; because some diseases act by more than one mechanism, certain disorders are listed more than once  (
         <a class="graphic graphic_table graphicRef112134" href="/z/d/graphic/112134.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The likely causes of pancytopenia are influenced by geography, socioeconomic conditions, and endemic illnesses. As examples, the likelihood of infectious (eg, malaria, tuberculosis, leishmaniasis) or nutritional causes (eg, folate deficiency) of pancytopenia may be increased in some resource-constrained settings [
         <a href="#rid6">
          6,7
         </a>
         ]. Similarly, the prevalence of human immunodeficiency virus (HIV) infection and alcohol use may influence the likely causes of pancytopenia.
        </p>
        <p>
         The vast majority of pancytopenia in adults is caused by acquired disorders; rarely, a previously unrecognized inborn error may account for cytopenias that are first detected in adulthood [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Other patient scenarios'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H805127821">
         <span class="h1">
          EMERGENCIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical stabilization is the highest priority for the patient with pancytopenia who is clinically unstable. Immediate hospitalization may be required to control life-threatening infections, provide blood product support, and/or manage other medical emergencies  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Pancytopenia associated with the following clinical situations will require immediate hematology consultation and/or hospitalization:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neutropenia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absolute neutrophil count (ANC) &lt;1000/microL with fever and/or other evidence of infection or other acute illness. (See
         <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">
          "Overview of neutropenic fever syndromes", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         New diagnosis of moderate or severe neutropenia (ie, ANC &lt;1000/microL and &lt;500/microL, respectively). (See
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia", section on 'Initial evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic anemia (eg, myocardial ischemia, hypotension). (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Symptomatic patient'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         New finding of platelets &lt;10,000/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinically significant bleeding with platelets &lt;50,000/microL. (See
         <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">
          "Diagnostic approach to thrombocytopenia in adults", section on 'Thrombocytopenic emergencies requiring immediate action'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspected disseminated intravascular coagulation (DIC), thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or other thrombotic microangiopathy because of schistocytes on peripheral blood smear accompanied by elevated lactate dehydrogenase. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspected acute leukemia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         New diagnosis (eg, circulating blasts). (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medical emergencies associated with leukemia (eg, DIC from acute promyelocytic leukemia, tumor lysis syndrome). (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Diagnostic evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">
          "Initial treatment of acute promyelocytic leukemia in adults", section on 'Emergency pretreatment evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17050.html" rel="external">
          "Tumor lysis syndrome: Prevention and treatment", section on 'Hypouricemic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspected severe aplastic anemia (ANC &lt;500/microL, platelets &lt;20,000/microL, anemia with reticulocyte count &lt;20,000/microL) or other bone marrow failure syndrome. (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspected hemophagocytic lymphohistiocytosis (HLH) because of unexplained fever, hepatomegaly, lymphadenopathy, and/or neurologic symptoms in association with very high serum ferritin, liver function abnormalities, and/or coagulopathy. (See
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic emergencies in the setting of pancytopenia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercalcemia with symptoms (eg, delirium, abdominal pain, dehydration) associated with the cause of pancytopenia (eg, multiple myeloma, metastatic cancer, adult T cell leukemia/lymphoma). (See
         <a class="medical medical_review" href="/z/d/html/4697.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/850.html" rel="external">
          "Treatment of hypercalcemia", section on 'Severe hypercalcemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute renal failure (eg, hyperkalemia, dehydration, fluid overload) associated with the cause of pancytopenia (eg, multiple myeloma, tumor lysis syndrome). (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults", section on 'Patients with a hyperkalemic emergency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">
          "Overview of the management of acute kidney injury (AKI) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperuricemia with renal failure associated with the cause of pancytopenia. (See
         <a class="medical medical_review" href="/z/d/html/17050.html" rel="external">
          "Tumor lysis syndrome: Prevention and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4085321792">
         <span class="h1">
          INITIAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         While there are numerous possible causes of pancytopenia, the differential diagnosis should narrow following an initial history and physical examination, screening laboratory studies, and examination of the peripheral blood smear  (
         <a class="graphic graphic_table graphicRef112134" href="/z/d/graphic/112134.html" rel="external">
          table 1
         </a>
         ). Initial testing should also identify emergency situations and determine the need for (and urgency of) hematology referral  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Emergencies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3424281101">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important considerations in the history include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Time course and clinical severity
         </strong>
         – Prior laboratory results (when available) and severity and duration of symptoms should be evaluated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms associated with cytopenias
         </strong>
         – Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent, severe, or unusual infections that may be due to leukopenia/neutropenia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fatigue, dyspnea, chest pain, hemodynamic instability, or claudication due to anemia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bleeding or easy bruising due to thrombocytopenia or disseminated intravascular coagulation
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Constitutional symptoms, including fevers, night sweats, and/or weight loss
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nausea, vomiting, and jaundice that may be associated with liver disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chest pain, hemodynamic instability, severe bleeding, life-threatening infections, and other medical emergencies may require immediate hospitalization for clinical stabilization  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Previous treatments
         </strong>
         – Determine if the patient has previously been treated for hematologic disorders, including prior transfusions, hematinics (eg, vitamin B12, folate, iron), or other treatments (eg, apheresis, plasma exchange).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other medical conditions
         </strong>
         – Almost any comorbid medical condition or surgical procedure can contribute to or exacerbate cytopenias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, a history of Crohn disease is relevant because the inflammatory bowel disease and previous surgeries may affect the patient’s nutritional status and impair absorption of essential nutrients and vitamins (eg, iron, folate, vitamin B12), while the inflammatory state may exacerbate anemia, and therapeutic agents may suppress bone marrow function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Problematic medications
         </strong>
         – Many medications (including prescription and over-the-counter medications, health supplements, and home or folk remedies) may cause or contribute to cytopenias  (
         <a class="graphic graphic_table graphicRef112133" href="/z/d/graphic/112133.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The relationship between the onset of pancytopenia and the administration of medications should be defined as much as possible. Some medications (eg, cytotoxic or immunosuppressive agents) cause predictable decreases in blood counts that are generally reversible if the agent is reduced or stopped. Other medications that are not commonly associated with dose-related cytopenias may cause idiosyncratic reactions leading to severe cytopenias. (See
         <a class="local">
          'Suspected medications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Personal and occupational exposures
         </strong>
         – Certain personal habits (eg, alcohol consumption, diet), infection history (eg, HIV, viral hepatitides), exposure to toxic agents at work or home (eg, organic solvents), and travel history (eg, exposure to malaria, leishmania) may also be relevant.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2955587970">
         <span class="h2">
          Physical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The physical examination
         <strong>
         </strong>
         may provide clues to the underlying etiology, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rashes that may be related to drug reactions, rheumatologic disorders, infections, and malignancies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral lesions; as examples, thrush suggests immune compromise; oral ulcers may be seen in diseases such as systemic lupus erythematosus
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphadenopathy and/or splenomegaly
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Jaundice and stigmata of liver disease
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H533547393">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial laboratory evaluation should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count (CBC), with white blood cell differential count and red blood cell indices
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination of the peripheral blood smear, which may reveal abnormalities that would not be detected by automated methods. (See
         <a class="local">
          'Abnormal cells on blood smear'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reticulocyte count. An absolute reticulocyte count &lt;20,000 indicates a marked decrease in red blood cell production and suggests a hypoproliferative condition. (See
         <a class="local">
          'Hypoproliferative conditions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prothrombin time (PT) and partial thromboplastin time (PTT). Coagulopathies in the setting of pancytopenia generally require prompt evaluation and referral. (See
         <a class="local">
          'Coagulopathy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum chemistry tests, including electrolytes, renal and liver function tests, lactate dehydrogenase, calcium, and uric acid. (See
         <a class="local">
          'Metabolic abnormalities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood type and screen
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2011641364">
         <span class="h2">
          Hematology referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Referral to a hematologist for purposes of diagnosis (eg, examination of the peripheral blood smear, bone marrow studies, interpretation of specialized molecular or flow cytometry results) and/or management is nearly always appropriate, unless an etiology is promptly identified that can be readily managed by the non-specialist clinician (eg, vitamin B12 or folate deficiency, alcoholic liver cirrhosis with congestive splenomegaly).
        </p>
        <p>
         The urgency of referral to a hematologist is influenced by the severity and trajectory of cytopenias, clinical stability, medical complications, and the need for urgent treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emergencies – Immediate hematology evaluation should be performed for the emergency situations described above, or in other settings of pancytopenia associated with clinical instability  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Emergencies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical stability – Referral is less urgent (eg, can occur within days to weeks) if the patient is asymptomatic, blood counts are stable and near normal, and there are no medical emergencies. Serial outpatient evaluation of complete blood counts and a review of the peripheral blood smear may be appropriate in select cases of asymptomatic, mild pancytopenia. The case should be discussed with a hematologist if there is uncertainty over the urgency of referral.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4294075745">
         <span class="h1">
          SUBSEQUENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential explanations for pancytopenia should emerge from the initial history, physical examination, screening laboratory studies, and review of the peripheral blood smear  (
         <a class="graphic graphic_table graphicRef112134" href="/z/d/graphic/112134.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         While a single underlying diagnosis should be sought, more than one potential cause or contributor to pancytopenia may be identified. (See
         <a class="local">
          'Multifactorial causes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2176385564">
         <span class="h2">
          Bone marrow and other specialized evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bone marrow aspirate and biopsy is useful in many, but not all, patients with pancytopenia. It is especially important in patients for whom a primary hematologic disorder is suspected as the cause of pancytopenia (eg, acute leukemia, aplastic anemia, multiple myeloma) or when the cause of pancytopenia remains elusive after the initial evaluation. The urgency of a bone marrow biopsy is influenced by the likely cause(s) of pancytopenia, as well as the severity and trajectory of cytopenias, clinical stability, medical complications, and the need for urgent treatment, as discussed in sections below. (See
         <a class="local">
          'Specific clinical scenarios'
         </a>
         below.)
        </p>
        <p>
         However, in certain situations, a bone marrow biopsy may be unhelpful or even distracting and confounding. As an example, a bone marrow biopsy performed just days after discontinuation of a suspect medication may show a "maturation arrest" (ie, recovery of bone marrow cells only up to an immature stage of differentiation) that may be morphologically indistinguishable from acute leukemia. Similarly, recent treatment with recombinant hematopoietic growth factors may induce a bone marrow morphology that is indistinguishable from certain myeloproliferative neoplasms or inflammatory conditions. In such situations it may be preferable to delay the biopsy by days to weeks.
        </p>
        <p>
         Bone marrow biopsies may also be uninformative in some cases when pancytopenia is thought to be due to peripheral blood cell destruction or sequestration (eg, suspected thrombocytopenic purpura, cirrhosis with hypersplenism); clinical evaluation and/or other specialized testing is generally more useful and definitive in such cases.
        </p>
        <p>
         The hematologist who will perform the procedure should communicate with a laboratory technician and/or pathologist to properly prepare the specimens (eg, place fresh aspirate material in appropriate anticoagulated medium for flow cytometry or molecular studies, and put biopsy specimens in proper fixative), and to order the appropriate tests.
        </p>
        <p>
         The bone marrow aspirate and biopsy specimens will undergo microscopic examination by a hematopathologist, pathologist, and/or hematologist; review by both the pathologist and involved clinicians can be invaluable in interpreting the bone marrow morphology in the context of the clinical presentation. (See
         <a class="medical medical_review" href="/z/d/html/4436.html" rel="external">
          "Bone marrow aspiration and biopsy: Indications and technique"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">
          "Evaluation of bone marrow aspirate smears"
         </a>
         .)
        </p>
        <p>
         The differential diagnosis of pancytopenia will inform further specialized testing of the bone marrow and/or peripheral blood (eg, flow cytometry, cytogenetics, molecular studies, microbiologic cultures). As an example, direct antiglobulin testing and flow cytometry may be needed to confirm the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytogenetic testing (fluorescent in situ hybridization [FISH] or karyotype) of bone marrow or peripheral blood may be required for confirmation of the diagnosis of many hematologic malignancies (eg, leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas). Molecular analysis is increasingly important in the diagnosis and risk stratification of many cancers, including hematologic malignancies. (See
         <a class="medical medical_review" href="/z/d/html/4482.html" rel="external">
          "General aspects of cytogenetic analysis in hematologic malignancies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14599.html" rel="external">
          "Personalized medicine", section on 'Cancer treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1081877583">
         <span class="h2">
          Specific clinical scenarios
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific clinical scenarios associated with pancytopenia are reviewed in this section.
        </p>
        <p class="headingAnchor" id="H4262008441">
         <span class="h3">
          Coagulopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The finding of elevated prothrombin time (PT) and/or partial thromboplastin time (PTT) in the setting of pancytopenia should focus immediate attention on determining if microangiopathic hemolytic anemia (MAHA) is present [
         <a href="#rid9">
          9
         </a>
         ]. This requires urgent examination of the peripheral blood smear by a hematologist or suitably experienced laboratory personnel for the presence of schistocytes with thrombocytopenia. The presence of MAHA may raise the possibility of DIC that may be due to sepsis, acute promyelocytic leukemia, or other causes. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
         If MAHA is not found, other explanations should be sought for the abnormal PT and/or PTT (eg, liver disease, vitamin K deficiency, medications). This evaluation may require mixing studies and/or specific coagulation factor tests to distinguish the presence of factor inhibitors from effects of medications, liver disease, or vitamin K deficiency. (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Evaluation of abnormal results'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3670740024">
         <span class="h3">
          Abnormal cells on blood smear
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormal cells on the peripheral smear should be examined by an experienced clinician to distinguish hematologic malignancies (eg, leukemia, lymphoma, myelodysplastic syndrome) from other disorders, such as infections (eg, atypical lymphocytes associated with viral or other infections), marrow replacement disorders (eg, myelofibrosis, metastatic cancer, multiple myeloma), and megaloblastic conditions. (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Worrisome findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H678851826">
         <span class="h4">
          Malignant disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of abnormal malignant cells on the blood smear of a pancytopenic patient include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Circulating blasts associated with leukemia; a substantial proportion of adults with pancytopenia are found to have acute leukemias, hairy cell leukemia, or other hematologic malignancies  (
         <a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid7">
          7,10-14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Blasts or tumor cells'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysplastic leukocytes, including pseudo-Pelger-Huët cells or reduced neutrophil cytoplasmic granules in myelodysplastic syndromes  (
         <a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef85881" href="/z/d/graphic/85881.html" rel="external">
          picture 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Blood smear'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immature myeloid cells, such as promyelocytes, myelocytes, and metamyelocytes that may reflect an underlying myeloproliferative neoplasm (MPN), such as primary myelofibrosis  (
         <a class="graphic graphic_picture graphicRef68110" href="/z/d/graphic/68110.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">
          "Clinical manifestations and diagnosis of primary myelofibrosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukoerythroblastic findings, including nucleated red blood cells associated with myelofibrosis or other MPNs  (
         <a class="graphic graphic_picture graphicRef68110" href="/z/d/graphic/68110.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Leukoerythroblastic smear'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Confirmation of the nature of such abnormal cells will require further specialized testing including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow aspirate and biopsy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry of peripheral blood and/or bone marrow
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytogenetic testing (fluorescent in situ hybridization [FISH] or karyotype) of bone marrow or peripheral blood
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Molecular studies (eg, mutation analysis, gene expression profiling)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3416656207">
         <span class="h4">
          Non-malignant cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormalities of granulocytes (eg, hypersegmented neutrophils), lymphocytes (eg, atypical lymphocytes associated with viral or other infections), and red blood cells (RBCs) (eg, ovalomacrocytes) may indicate disorders other than hematologic malignancies.
        </p>
        <p>
         Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypersegmented neutrophils (ie, five or more nuclear lobes) in association with ovalomacrocytes (ie, enlarged, ovoid RBCs) suggest a megaloblastic disorder  (
         <a class="graphic graphic_picture graphicRef58820" href="/z/d/graphic/58820.html" rel="external">
          picture 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Lobulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common causes of these findings are deficiencies of folate and/or vitamin B12. The appearance of the peripheral blood smear is indistinguishable between these two vitamin deficiencies, and establishing the diagnosis requires specific testing. It is important to note that serum folate levels may quickly normalize after feeding a malnourished patient, but RBC folate will more accurately reflect the prior state. (See
         <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">
          "Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atypical lymphocytes (lymphoid cells with generous and malleable cytoplasm, often indented by surrounding red cells) can be seen during or following viral infections such as infectious mononucleosis, and may be associated with pancytopenia due to bone marrow suppression, hypersplenism, and other mechanisms  (
         <a class="graphic graphic_picture graphicRef55986" href="/z/d/graphic/55986.html" rel="external">
          picture 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Lymphocytes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukoerythroblastic appearance of the blood smear, with RBC teardrops, nucleated RBCs, and microangiopathic hemolytic anemia (MAHA), may be associated bone marrow infiltration caused by myelofibrosis or metastatic cancer  (
         <a class="graphic graphic_picture graphicRef68110" href="/z/d/graphic/68110.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7140.html" rel="external">
          "Causes of anemia in patients with cancer", section on 'Overview'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Schistocytes or other evidence of MAHA may reflect disseminated intravascular coagulation, due to sepsis, acute promyelocytic leukemia, or other causes. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3739889997">
         <span class="h3">
          Hypoproliferative conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reticulocytopenia (ie, &lt;20,000 reticulocytes/microL) may indicate a hypoproliferative pancytopenia. The urgency and the pace of further evaluation should be influenced by the severity and trajectory of the cytopenias, and the presence of symptoms or complications of the cytopenias. Suspected severe aplastic anemia (absolute neutrophil count [ANC] &lt;500/microL, platelets &lt;20,000/microL), along with reticulocytopenia requires emergency evaluation. (See
         <a class="local">
          'Emergencies'
         </a>
         above.)
        </p>
        <p>
         Other diagnostic considerations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deficiencies of essential vitamins or minerals (eg, vitamin B12, folate, or copper) [
         <a href="#rid15">
          15,16
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications (eg, cytotoxic agents, or idiosyncratic drug reactions)  (
         <a class="graphic graphic_table graphicRef112133" href="/z/d/graphic/112133.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow suppression (eg, alcohol, viral infections)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aplastic anemia (eg, autoimmune/idiopathic, which may be associated with paroxysmal nocturnal hemoglobinuria; or associated with drugs, viral infections, or toxins) [
         <a href="#rid17">
          17-19
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ineffective hematopoiesis (eg, myelodysplastic syndromes, megaloblastic conditions)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow infiltration/replacement (eg, myelofibrosis, metastatic cancer, storage diseases) [
         <a href="#rid20">
          20
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancies associated with immune suppression (eg, hairy cell leukemia, T cell large granular lymphocyte leukemia)
        </p>
        <p>
        </p>
        <p>
         Defining the nature of a hypoproliferative bone marrow condition usually requires testing the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum vitamin B12, folate, and/or copper (as appropriate)
        </p>
        <p>
        </p>
        <p>
         If testing for vitamin B12 and folate is unrevealing, and the history does not suggest alcohol, infections, or reactions to medications as a cause of hypoproliferative pancytopenia, further testing may be required:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow aspirate and biopsy, with consideration of immunohistochemical staining, flow cytometry, and other specialized testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serologic studies to evaluate viral etiologies or autoimmune illnesses (perhaps in concert with specialists in infectious diseases or rheumatology).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry of peripheral blood (eg, for CD59) may be useful when paroxysmal nocturnal hemoglobinuria (PNH) is associated with aplastic anemia [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria", section on 'Diagnosis and classification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1103610244">
         <span class="h3">
          Splenomegaly and/or liver disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of splenomegaly and pancytopenia suggests hypersplenism (ie, sequestration and/or excessive destruction of blood cells in an enlarged spleen). All cell lineages may be affected.
        </p>
        <p>
         In many, but not all cases, splenomegaly and hypersplenism are associated with liver disease. Conversely, other conditions can cause liver disease and pancytopenia without splenomegaly.
        </p>
        <p>
         The extent of cytopenias in hypersplenism is variable, but generally less severe than that caused by primary bone marrow disorders. However, splenomegaly and liver disease are associated with many disorders that also contribute to cytopenias by other mechanisms (eg, malignancies, myelofibrosis, infections), and the resultant multifactorial cytopenias may be severe. (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Evaluation (splenomegaly)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests", section on 'Initial evaluation'
         </a>
         .)
        </p>
        <p>
         Conditions associated with pancytopenia in the setting of splenomegaly and/or liver disease include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver disease/cirrhosis and portal hypertension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections (eg, viral infections, malaria, leishmaniasis, endocarditis) [
         <a href="#rid6">
          6,22-29
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic malignancies (eg, lymphomas, hairy cell leukemia, myeloproliferative neoplasms)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extramedullary hematopoiesis (eg, associated with myelofibrosis or thalassemias)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congestion (eg, right sided congestive heart failure)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammation (eg, associated with rheumatoid arthritis [Felty syndrome] or other autoimmune illness, endocarditis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary splenic disease (eg, hemorrhage, thrombosis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Storage diseases (eg, Gaucher disease)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemophagocytic lymphohistiocytosis
        </p>
        <p>
        </p>
        <p>
         The differential diagnosis of pancytopenia in the setting of splenomegaly is influenced by the presence of concurrent lymphadenopathy, constitutional symptoms, stigmata of chronic liver disease, and findings of autoimmune disorders. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of both splenomegaly and lymphadenopathy may suggest an underlying hematologic malignancy (eg, lymphoma, leukemia), infectious disease, or autoimmune disorder. (See
         <a class="local">
          'Lymphadenopathy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stigmata of chronic liver disease may suggest pancytopenia caused by hypersplenism from cirrhosis. If no explanation for the underlying liver disease is readily identified, evaluation of the liver by imaging (eg, ultrasound, CT scan) and/or biopsy may be warranted. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities of liver function without stigmata of chronic liver disease or splenomegaly may be associated with infectious diseases (eg, acute viral hepatitis), medications, autoimmune disorders, or hemophagocytic lymphohistiocytosis as potential causes of pancytopenia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2522887715">
         <span class="h3">
          Lymphadenopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of lymphadenopathy (localized or generalized) may provide important information regarding the underlying cause of pancytopenia.
        </p>
        <p>
         Potential disorders associated with lymphadenopathy and pancytopenia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic malignancies (eg, lymphoma, leukemia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune illnesses
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infectious diseases
        </p>
        <p>
        </p>
        <p>
         Aids to the diagnosis of an underlying cause of lymphadenopathy in the setting of pancytopenia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging (eg, CT scan, ultrasound, or PET scan to define the extent of lymphadenopathy, and as a possible adjunct to biopsy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymph node biopsy (including morphology, flow cytometry, molecular studies)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry of peripheral blood and/or lymph node specimen (eg, to evaluate for hematologic malignancies)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serologic studies for infectious or autoimmune illnesses
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow aspirate and biopsy may be required if other studies are non-diagnostic
        </p>
        <p>
        </p>
        <p>
         Evaluation of the patient with lymphadenopathy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8386.html" rel="external">
          "Evaluation of peripheral lymphadenopathy in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2020507350">
         <span class="h3">
          Autoimmune conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Variable degrees of pancytopenia are commonly seen in patients with previously diagnosed autoimmune illnesses. Rheumatoid arthritis/Felty syndrome, systemic lupus erythematosus, and sarcoidosis are often associated with cytopenias, and some of the treatments for these illnesses (eg, gold salts, cytotoxic agents) may exacerbate the cytopenias. (See
         <a class="medical medical_review" href="/z/d/html/7512.html" rel="external">
          "Hematologic complications of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
         Furthermore, autoimmune diseases are often associated with other conditions that can cause pancytopenia (eg, pernicious anemia, thyroid disease, T cell large granular lymphocyte leukemia [T-LGL]) [
         <a href="#rid30">
          30
         </a>
         ]. Thus, pancytopenia in the setting of autoimmune illnesses is frequently multifactorial. (See
         <a class="medical medical_review" href="/z/d/html/7482.html" rel="external">
          "Clinical manifestations and diagnosis of Felty syndrome"
         </a>
         .)
        </p>
        <p>
         An important component of the management of cytopenias in the setting of known autoimmune illness is identifying conditions that may be contributing to the cytopenias.
        </p>
        <p>
         Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated disorders should be sought and managed (eg, folate deficiency, vitamin B12 deficiency associated with pernicious anemia, autoimmune thyroid disease)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alternative therapeutic agents may be considered (in consultation with the clinician managing the autoimmune illness) in an effort to lessen bone marrow suppression and inflammation. (See
         <a class="medical medical_review" href="/z/d/html/7486.html" rel="external">
          "Drug therapy in Felty syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consideration may be given to splenectomy in some patients with symptomatic Felty syndrome. (See
         <a class="medical medical_review" href="/z/d/html/7485.html" rel="external">
          "Role of splenectomy for Felty syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If T-LGL is suspected, evaluation by flow cytometry of peripheral blood or bone marrow aspirate/biopsy should be considered. (See
         <a class="medical medical_review" href="/z/d/html/16360.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia", section on 'Pathologic features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In some patients, a "forme fruste" of an autoimmune illness may be suspected, but no firm diagnosis has been established. (See
         <a class="local">
          'Other patient scenarios'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2354826801">
         <span class="h3">
          Constitutional symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancytopenia may present in the setting of otherwise unexplained fevers, soaking sweats, and weight loss. It may be especially important to consider an infectious etiology or hemophagocytic lymphohistiocytosis in this setting. Possible causes of pancytopenia associated with constitutional symptoms include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infections (viral illness, miliary tuberculosis, fungal infection, endocarditis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemophagocytic lymphohistiocytosis (HLH)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic malignancies (eg, lymphoma, leukemia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune illnesses
        </p>
        <p>
        </p>
        <p>
         The presence of lymphadenopathy, liver disease, splenomegaly, or other findings can provide important clues to the nature of the underlying illness, and the evaluation in these settings is discussed above. (See
         <a class="local">
          'Splenomegaly and/or liver disease'
         </a>
         above and
         <a class="local">
          'Lymphadenopathy'
         </a>
         above.)
        </p>
        <p>
         In some patients, constitutional symptoms may be the only apparent clinical findings. Establishing the diagnosis in such a setting may be challenging. If no likely diagnosis presents itself, and especially if the cytopenias are severe or associated with symptoms and/or complications, a bone marrow aspirate and biopsy with specialized infectious disease evaluation of the bone marrow specimen (eg, fungal and/or mycobacterial cultures and stains) should be performed, as appropriate. Other aspects of the evaluation of patients with otherwise unexplained fever and other constitutional symptoms are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2768.html" rel="external">
          "Evaluation of the patient with night sweats or generalized hyperhidrosis", section on 'Initial assessment of all patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2736.html" rel="external">
          "Fever of unknown origin in adults: Evaluation and management", section on 'Targeted testing'
         </a>
         .)
        </p>
        <p>
         A high index of suspicion must be maintained for the presence of HLH in the setting of pancytopenia associated with constitutional symptoms but no other clinical findings [
         <a href="#rid31">
          31-33
         </a>
         ]. Diagnosis of HLH is supported by the following (see
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Evaluation and diagnostic testing'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ferritin – Serum ferritin is usually very high (often &gt;5000 ng/mL) and has high specificity in children, but not in adults [
         <a href="#rid34">
          34
         </a>
         ]; however, a ferritin &lt;500 ng/mL has excellent negative predictive value for excluding the diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver function tests (LFTs) – While not one of the diagnostic criteria for HLH, elevated liver enzymes (AST, ALT, GGT), lactate dehydrogenase (LDH), and bilirubin are elevated in nearly all patients
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypofibrinogenemia – This may often be out of proportion to other coagulation parameters
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triglycerides – Marked elevation of triglycerides is typically seen, especially with severe liver involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Soluble CD25 – Elevated soluble IL-2 receptor alpha (sIL-2R or sCD25)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NK cell function – Low/absent NK cell function/degranulation by flow cytometry (in children but not adults)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow biopsy – Findings of hemophagocytosis and/or infiltration by activated macrophages
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organomegaly – Splenomegaly and/or hepatomegaly may be present
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H156270022">
         <span class="h3">
          Metabolic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain metabolic disorders (eg, hypercalcemia, tumor lysis syndrome, renal failure, hyperuricemia) may be associated with diseases that also cause pancytopenia, including multiple myeloma, leukemia, and lymphoma [
         <a href="#rid35">
          35,36
         </a>
         ]. The association of these metabolic complications with pancytopenia may constitute a medical emergency, and require urgent hospitalization and/or referral to a hematologist for establishing the diagnosis and initiating prompt management  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         If an underlying diagnosis is known but was not previously associated with pancytopenia, the clinician must investigate causes for the decline in blood counts. The cause(s) will often be multifactorial, but consideration should be given to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review of disease status to assess progressive disease or treatment resistance, including restaging of lymphomas or myeloma (eg, repeat CT or PET-CT scans, serologic evaluation of multiple myeloma)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of a fundamental change in the disease (eg, Richter transformation of a previously diagnosed lymphoma, progression of myelodysplastic syndrome to acute leukemia) may require repeat bone marrow or lymph node biopsy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complications of treatment (eg, drug-associated bone marrow aplasia, treatment-associated leukemia)
        </p>
        <p>
        </p>
        <p>
         Further evaluation and management of these disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4510.html" rel="external">
          "Acute myeloid leukemia: Overview of complications", section on 'Tumor lysis syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">
          "Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1426304778">
         <span class="h3">
          Suspected medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a particular medication is suspected as a cause of pancytopenia, consideration should be given to discontinuing that medication (or perhaps reducing the dose) in consultation with other treating clinicians. This decision will be influenced by the severity of the cytopenias, the trajectory of the blood counts, clinical symptoms, and the reason why the medication is being administered.
        </p>
        <p>
         For cytotoxic or myelosuppressive agents, blood count recovery can generally be expected within days to weeks. When such drugs are thought to be the cause of pancytopenia, it may be preferable to observe the blood counts for one or two weeks rather than immediately performing a bone marrow biopsy.
        </p>
        <p>
         When an idiosyncratic reaction is a likely cause of pancytopenia, a response to discontinuing the medication is less predictable and recovery of blood counts may be protracted. The clinical presentation and the appearance of the bone marrow in such situations may be indistinguishable from idiopathic aplastic anemia. The clinician’s judgment is needed to distinguish between these diagnostic possibilities, since confirmatory tests are rarely available or conclusive.
        </p>
        <p>
         An immediate bone marrow biopsy may not be helpful when a medication is suspected to be the cause of pancytopenia. A finding of aplasia or hypoplasia will not confirm the identity or nature of the etiologic agent. Additionally, if a biopsy is performed early in the recovery process, the bone marrow may erroneously suggest an acute leukemia, because the recovering cells may exhibit a “maturation arrest” as hematopoiesis has only progressed to an immature stage of maturation. In such a clinical setting, serial observation of the patient and blood counts may be the most useful diagnostic approach.
        </p>
        <p>
         Mechanisms of drug-associated cytopenias include allergic reactions that affect bone marrow production and/or increase peripheral destruction, and pseudo-allergic reactions. Allergic reactions may be influenced by the patient’s immunologic background (ie, HLA type), comorbid conditions, pharmacogenomic constitution [
         <a href="#rid37">
          37
         </a>
         ], prior exposure to that medication or related drugs, and other clinical features. Exposure to some drugs can induce a hypoproliferative pancytopenia that may be indistinguishable from idiopathic aplastic anemia; recovery of blood counts during a period of observation after discontinuing the suspect medication, if clinically reasonable, may help to distinguish between these diagnoses  (
         <a class="graphic graphic_table graphicRef112133" href="/z/d/graphic/112133.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2780367756">
         <span class="h3">
          Multifactorial causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Often, more than one disorder may contribute to pancytopenia, a so-called multifactorial pancytopenia.
        </p>
        <p>
         Examples include:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alcohol use, folate deficiency, cirrhosis, splenomegaly
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HIV infection, multiple medications, AIDS-associated lymphoma
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autoimmune disorder, splenomegaly, multiple medications
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lymphoma with autoimmune cytopenias, cytotoxic medications
        </p>
        <p>
        </p>
        <p>
         Many other such multifactorial clinical pictures are encountered in the evaluation of pancytopenia. In such a setting, it is important to identify reversible or treatable causes of cytopenias. As examples, treatment of vitamin deficiencies, discontinuation of suspect medications, and identification of other treatable conditions should be a high priority in evaluating and managing patients with multifactorial pancytopenia.
        </p>
        <p class="headingAnchor" id="H2109699438">
         <span class="h3">
          Other patient scenarios
         </span>
         <span class="headingEndMark">
          —
         </span>
         The scenarios presented above offer a starting point for the evaluation of pancytopenia in many patients. The pace of diagnostic evaluation will be influenced by the severity and trajectory of the cytopenias and the patient’s clinical status (eg, presence of medical emergencies, clinical stability, and associated symptoms).
        </p>
        <p>
         Relatively stable patients with mild cytopenias may undergo an outpatient diagnostic work-up with serial evaluation of blood counts. If the counts decline, complications of cytopenias develop, and/or the evaluation is unrevealing, bone marrow examination should be considered.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Young patient with mild cytopenias
         </strong>
         – A younger adult with mild, asymptomatic pancytopenia may have no definitive clinical findings to suggest the cause of the cytopenias. The history may reveal family members with autoimmune conditions, thyroid disease, or pernicious anemia, and the patient may have vague musculoskeletal symptoms, but does not meet diagnostic criteria for an autoimmune disorder. In some such cases, this may represent a "forme fruste" of an autoimmune disorder and the cytopenias may be identified before other manifestations of the disorder. In others, the cytopenias may reflect recovery from a viral infection or reaction to a medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A bone marrow biopsy may not be helpful in this setting, as no diagnostic abnormalities may be identified, unless there is suspicion of an associated immune disorder or lymphoma. Such an asymptomatic patient with mild pancytopenia may have serial outpatient evaluation of complete blood counts and a review of the peripheral blood smear and be counseled about monitoring symptoms; the case should be discussed with a hematologist if there is uncertainty over the urgency of referral.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adult presentation of inborn abnormalities
         </strong>
         – Rare patients will present with late onset congenital disorders. The patient may have had mild, longstanding cytopenias that were not evaluated or for which initial diagnostic testing was unrevealing. In some cases, findings that were previously dismissed (eg, premature graying of the hair, abnormalities of fingernails or skeleton) may be related to an underlying congenital abnormality [
         <a href="#rid8">
          8
         </a>
         ]. Monocytopenia, recurrent viral infections, disseminated nontuberculous mycobacterial infections, opportunistic fungal infections, pulmonary alveolar proteinosis, and primary lymphedema may suggest GATA2 deficiency. A family history of liver cirrhosis or pulmonary fibrosis raises the possibility of a telomere biology disorder. (See
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1091515062">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120173.html" rel="external">
          "Society guideline links: Bone marrow failure syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H223114421">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Pancytopenia refers to a decrease in ≥2 blood lineages. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Values may differ among laboratories, but we use the following criteria:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemoglobin (Hb)
         </strong>
         – Men &lt;13 g/dL; non-pregnant women &lt;12 g/dL
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Absolute neutrophil count (ANC)
         </strong>
         – ANC &lt;1800/microL (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Platelets
         </strong>
         – Platelets &lt;150,000/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms
         </strong>
         – Pancytopenia may be caused by bone marrow aplasia, marrow infiltration/replacement, ineffective hematopoiesis, and/or excessive blood cell destruction or sequestration  (
         <a class="graphic graphic_table graphicRef112134" href="/z/d/graphic/112134.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Mechanisms of pancytopenia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical
         </strong>
         – History and examination should evaluate the severity, time course, and trajectory of pancytopenia (if available); fatigue, dyspnea, infections, and bleeding/bruising; medications  (
         <a class="graphic graphic_table graphicRef112133" href="/z/d/graphic/112133.html" rel="external">
          table 3
         </a>
         ); toxic exposures; comorbid illnesses; and relevant physical findings  (
         <a class="graphic graphic_table graphicRef112133" href="/z/d/graphic/112133.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Initial evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory
         </strong>
         (see
         <a class="local">
          'Laboratory studies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complete blood count (CBC) with differential count
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Reticulocyte count
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Blood smear
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Prothrombin time/partial thromboplastin time (PT/PTT)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Blood type and screen
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complete metabolic panel
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergencies
         </strong>
         – Certain conditions may require urgent diagnostic evaluation, management, and/or hospitalization, including  (
         <a class="graphic graphic_table graphicRef112135" href="/z/d/graphic/112135.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Emergencies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Febrile neutropenia
         </strong>
         – Fever or other infectious findings associated with neutropenia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic anemia
         </strong>
         – Cardiac symptoms, including ischemia, hemodynamic instability, or worsening congestive heart failure
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe or symptomatic thrombocytopenia
         </strong>
         – Platelets &lt;10,000/microL or &lt;50,000/microL in association with bleeding
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Abnormal blood smear
         </strong>
         – Microangiopathy or blasts on smear
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Further evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinically stable with mild cytopenias
         </strong>
         – For milder cytopenias and no clinical complications, it may be satisfactory to monitor the patient closely over days to a few weeks without immediate diagnostic evaluation. Examples include a recent viral infection, alcohol overuse, myelosuppressive agents and other medications, or suspected folate or vitamin B12 deficiency. (See
         <a class="local">
          'Subsequent evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, further evaluation is needed if blood counts decline, no clinical improvement is observed, and/or complications arise.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other scenarios
         </strong>
         – For patients without a readily explained or reversible cause of cytopenias, diagnostic evaluation with a bone marrow (BM) examination, with or without flow cytometry is needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Examples of specific scenarios include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Suspected hematologic malignancy
         </strong>
         – Circulating blasts or other immature myeloid cells  (
         <a class="graphic graphic_picture graphicRef78291" href="/z/d/graphic/78291.html" rel="external">
          picture 1
         </a>
         ), dysplastic features  (
         <a class="graphic graphic_picture graphicRef85881" href="/z/d/graphic/85881.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef71990" href="/z/d/graphic/71990.html" rel="external">
          picture 2
         </a>
         ), or other clinical findings or laboratory features that suggest an acute leukemia, myelodysplastic syndrome (MDS), lymphoma, or other hematologic malignancy should be evaluated as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Aplastic anemia
         </strong>
         – For severe cytopenias without an abnormal blood smear, aplastic anemia should be evaluated with a BM examination, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">
          "Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Suspected inherited disorder
         </strong>
         – An inherited condition should be considered for a patient with unexplained cytopenias, characteristic somatic abnormalities, or such a family history. Evaluation and diagnosis of Fanconi anemia, telomere disorders, and other inherited conditions are described separately. (See
         <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">
          "Clinical manifestations and diagnosis of Fanconi anemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3932371675">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge John M Gansner, MD, PhD who contributed to an earlier version of this topic review.
        </p>
        <p>
         The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology Am Soc Hematol Educ Program 2012; 2012:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS, Abkowitz JL, Luzzatto L. New Insights into the Pathophysiology of Acquired Cytopenias. Hematology Am Soc Hematol Educ Program 2000; :18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascutti MF, Erkelens MN, Nolte MA. Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output. Front Immunol 2016; 7:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks PW. Hematologic manifestations of liver disease. Semin Hematol 2013; 50:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risitano AM, Maciejewski JP, Selleri C, Rotoli B. Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. Curr Stem Cell Res Ther 2007; 2:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain A, Naniwadekar M. An etiological reappraisal of pancytopenia - largest series reported to date from a single tertiary care teaching hospital. BMC Hematol 2013; 13:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinzierl EP, Arber DA. Bone marrow evaluation in new-onset pancytopenia. Hum Pathol 2013; 44:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devitt KA, Lunde JH, Lewis MR. New onset pancytopenia in adults: a review of underlying pathologies and their associated clinical and laboratory findings. Leuk Lymphoma 2014; 55:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohn SK, Suh JS, Lee J, Lee KB. Pancytopenic prodrome (pre-ALL) of acute lymphoblastic leukemia in adults: possible pathogenesis. Korean J Intern Med 1998; 13:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhargava R, Kar R, Mahapatra M, Saxena R. The clinico-hematological profile of hairy cell leukaemia: a single centre experience. Hematology 2010; 15:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galani KS, Subramanian PG, Gadage VS, et al. Clinico-pathological profile of Hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol 2012; 55:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somasundaram V, Purohit A, Aggarwal M, et al. Hairy cell leukemia: A decade long experience of North Indian Hematology Center. Indian J Med Paediatr Oncol 2014; 35:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabreyes AA, Abbasi HN, Forbes KP, et al. Hypocupremia associated cytopenia and myelopathy: a national retrospective review. Eur J Haematol 2013; 90:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabel AL, Gaudiani JL, Statland B, Mehler PS. Hematological abnormalities in severe anorexia nervosa. Ann Hematol 2013; 92:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy RN, Sawitsky A, Florman AL, Rubin E. Fatal aplastic anemia after hepatitis. Report of five cases. N Engl J Med 1965; 273:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeldis JB, Dienstag JL, Gale RP. Aplastic anemia and non-A, non-B hepatitis. Am J Med 1983; 74:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992; 71:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria. Am J Hematol 2014; 89:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mir N, Costello C, Luckit J, Lindley R. HIV-disease and bone marrow changes: a study of 60 cases. Eur J Haematol 1989; 42:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyeyune R, Saathoff E, Ezeamama AE, et al. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis 2014; 14:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehehalt U, Schunk M, Jensenius M, et al. Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study. Travel Med Infect Dis 2014; 12:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosilkovski M, Krteva L, Dimzova M, et al. Human brucellosis in Macedonia - 10 years of clinical experience in endemic region. Croat Med J 2010; 51:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           et al, Gonen I, Sozen H, Kayal O. Brucellosis: Evaluation of 201 cases in an endemic area of Mediterranean Basin. Acta Medica Mediterranea 2014; 30:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Achi HV, Ahui BJ, Anon JC, et al. [Pancytopenia: a severe complication of miliary tuberculosis]. Rev Mal Respir 2013; 30:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfromm A, Rodriguez C, Michel M, et al. Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice. Br J Haematol 2015; 170:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 2014; 89:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 2015; 90:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li F, Yang Y, Jin F, et al. Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis 2015; 10:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 2015; 125:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011; 18:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 2014; 21:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton JF, Stacey M, Kearns WG, et al. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr Blood Cancer 2004; 42:122.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13938 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23233623" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Low blood counts: immune mediated, idiopathic, or myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11701533" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : New Insights into the Pathophysiology of Acquired Cytopenias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27695457" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23953338" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hematologic manifestations of liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18220891" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24238033" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An etiological reappraisal of pancytopenia - largest series reported to date from a single tertiary care teaching hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23332933" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Bone marrow evaluation in new-onset pancytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20417588" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pathophysiology and management of inherited bone marrow failure syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25119611" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Syndromes of thrombotic microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23829306" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : New onset pancytopenia in adults: a review of underlying pathologies and their associated clinical and laboratory findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9538635" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pancytopenic prodrome (pre-ALL) of acute lymphoblastic leukemia in adults: possible pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20557675" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The clinico-hematological profile of hairy cell leukaemia: a single centre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22499303" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinico-pathological profile of Hairy cell leukemia: critical insights gained at a tertiary care cancer hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25538404" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hairy cell leukemia: A decade long experience of North Indian Hematology Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23034053" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hypocupremia associated cytopenia and myelopathy: a national retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23392575" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hematological abnormalities in severe anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5841674" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fatal aplastic anemia after hepatitis. Report of five cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6295145" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Aplastic anemia and non-A, non-B hepatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16778145" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Current concepts in the pathophysiology and treatment of aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1435229" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24127129" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Laboratory tests for paroxysmal nocturnal hemoglobinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2721658" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : HIV-disease and bone marrow changes: a study of 60 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25209550" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24388687" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Leishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20718086" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Human brucellosis in Macedonia - 10 years of clinical experience in endemic region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Brucellosis: Evaluation of 201 cases in an endemic area of Mediterranean Basin
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23318187" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : [Pancytopenia: a severe complication of miliary tuberculosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393033" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25920561" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20378561" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24581757" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25469675" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25757854" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25573993" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Marked hyperferritinemia does not predict for HLH in the adult population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21897221" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mechanisms and treatment of hypercalcemia of malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359983" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Tumor lysis syndrome: new challenges and recent advances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14752874" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
